Gyre Therapeutics Inc (NAS:GYRE)
$ 6.3 +0.080 (+1.29%) Market Cap: 702.38 Mil Enterprise Value: 689.07 Mil PE Ratio: 0 PB Ratio: 5.68 GF Score: 39/100

Catalyst Biosciences Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript

Sep 17, 2020 / 09:00PM GMT
Frank Tang;Morgan Stanley;Analyst

Good afternoon, everyone, and welcome to the 2020 Morgan Stanley Healthcare Conference. I am Frank Tang from Morgan Stanley.

Before we get started, we have a quick disclaimer. Please note that this webcast is for Morgan Stanley clients and appropriate Morgan Stanley employees only. This webcast is not for members of the press. If you are a member of the press, please disconnect and reach out separately. For important disclosures, please see Morgan Stanley Research Disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative.

Okay. With that out of the way today, I am joined by the team at Catalyst Biosciences, Nassim Usman, President and CEO; Clinton Musil, CFO; Howard Levy, Chief Medical Officer; Grant Blouse, SVP of Translational Research.

In terms of format, we will start by having Nassim briefly go through a short presentation, and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot